UK markets closed

Rigel Pharmaceuticals Inc (RI2A.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
0.9070-0.1000 (-9.93%)
At close: 08:05AM CEST
Full screen
Previous close1.0070
Open0.9070
Bid0.9250 x 500000
Ask0.9610 x 500000
Day's range0.9070 - 0.9070
52-week range0.6678 - 1.6345
Volume0
Avg. volume325
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • PR Newswire

    Rigel Reports First Quarter 2024 Financial Results and Provides Business Update

    Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2024, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment and sales of REZLIDHIA® (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitr

  • PR Newswire

    Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update

    Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2024 financial results after market close on Tuesday, May 7, 2024. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.

  • PR Newswire

    Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 407,325 stock options to nine non-executive employees on April 4, 2024, and 187,500 stock options to Lisa Rojkjaer, Rigel's Chief